Holen Sie sich die Stockscreener-App
11.91
3.01%
-0.37
Schlusskurs vom Vortag:
$12.28
Offen:
$12.28
24-Stunden-Volumen:
927.01K
Relative Volume:
0.68
Marktkapitalisierung:
$1.04B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-185.15M
KGV:
-5.8806
EPS:
-2.0253
Netto-Cashflow:
$-148.72M
1W Leistung:
-5.78%
1M Leistung:
+21.28%
6M Leistung:
-57.59%
1J Leistung:
+145.57%
1-Tages-Spanne:
$11.43
$12.28
1-Wochen-Bereich:
$11.43
$13.09
52-Wochen-Spanne:
$4.37
$36.26
Olema Pharmaceuticals Inc Stock (OLMA) Company Profile
Firmenname
Olema Pharmaceuticals Inc
Sektor
Branche
Telefon
(415) 651-3316
Adresse
780 BRANNAN STREET, SAN FRANCISCO
Compare OLMA vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OLMA
Olema Pharmaceuticals Inc
|
11.91 | 1.04B | 0 | -185.15M | -148.72M | -2.0253 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Olema Pharmaceuticals Inc Stock (OLMA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-27 | Eingeleitet | Wolfe Research | Peer Perform |
| 2026-03-19 | Fortgesetzt | Jefferies | Buy |
| 2026-02-11 | Eingeleitet | Stifel | Buy |
| 2026-01-07 | Eingeleitet | Piper Sandler | Overweight |
| 2025-10-08 | Eingeleitet | Guggenheim | Buy |
| 2025-08-12 | Bestätigt | Citigroup | Buy |
| 2024-04-02 | Eingeleitet | Goldman | Buy |
| 2024-01-30 | Eingeleitet | Citigroup | Buy |
| 2023-07-21 | Eingeleitet | Oppenheimer | Outperform |
| 2023-05-05 | Eingeleitet | CapitalOne | Overweight |
| 2023-02-22 | Eingeleitet | Credit Suisse | Outperform |
| 2022-07-06 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-06-09 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2022-02-28 | Eingeleitet | H.C. Wainwright | Neutral |
| 2021-12-07 | Fortgesetzt | Cowen | Outperform |
| 2020-12-14 | Eingeleitet | Canaccord Genuity | Buy |
| 2020-12-14 | Eingeleitet | Cowen | Outperform |
| 2020-12-14 | Eingeleitet | JP Morgan | Overweight |
| 2020-12-14 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Olema Pharmaceuticals Inc Aktie (OLMA) Neueste Nachrichten
Enterprise value to EBIT forward of Olema Pharmaceuticals, Inc. – NASDAQ:OLMA - TradingView
Price to earnings forward of Olema Pharmaceuticals, Inc. – NASDAQ:OLMA - TradingView
Price to earnings forward of Olema Pharmaceuticals, Inc. – BOATS:OLMA - TradingView
Price to book forward of Olema Pharmaceuticals, Inc. – NASDAQ:OLMA - TradingView
OLMA News | OLEMA PHARMACEUTICALS INC (NASDAQ:OLMA) - ChartMill
Enterprise value to EBITDA forward of Olema Pharmaceuticals, Inc. – NASDAQ:OLMA - TradingView
Enterprise value to EBITDA forward of Olema Pharmaceuticals, Inc. – BOATS:OLMA - TradingView
Enterprise value to revenue forward of Olema Pharmaceuticals, Inc. – NASDAQ:OLMA - TradingView
Olema Pharmaceuticals (OLMA) Q1 2026 Earnings: Narrower-Than-Expected Loss Lifts SharesInvestor Earnings Call - dars.gov.et
LifeSci Capital Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Maintains Target Price $24 - Moomoo
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Olema Oncology awards 215,800 options to eight new employees - Stock Titan
Olema Pharmaceuticals opens director clinical science role to advance cancer trial programs - Traders Union
Olema Pharmaceuticals (OLMA) Is Up 22.0% After Broad Russell Growth Index InclusionHas The Bull Case Changed? - simplywall.st
Does Olema Pharmaceuticals' (OLMA) Broad Russell Growth Inclusion Reveal a Turning Point in Its Investor Story? - Yahoo Finance
Olema Pharmaceuticals, Inc.(NasdaqGS:OLMA) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Olema Pharmaceuticals, Inc.(NasdaqGS: OLMA) added to Russell 2500 Growth Benchmark - marketscreener.com
Olema Pharmaceuticals, Inc.(NasdaqGS:OLMA) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Olema Pharmaceuticals, Inc.(NasdaqGS: OLMA) added to Russell 2000 Growth Benchmark - marketscreener.com
Olema Pharmaceuticals, Inc.(NasdaqGS:OLMA) added to Russell 3000E Growth Benchmark - marketscreener.com
Olema Pharmaceuticals (OLMA) Holds Steady Near Support Amid Minor DeclineUp Down Volume - dars.gov.et
Olema Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:OLMA) - TradingView
OLMA Forecast — Price Target — Prediction for 2027 - TradingView
Form 4 Olema Pharmaceuticals Inc For: 23 June By Investing.com - Investing.com Australia
Olema (NASDAQ: OLMA) awards director 29,500 stock options - Stock Titan
BVF group (NASDAQ: OLMA) reports 29,500 new options and large pre-funded warrants - Stock Titan
Olema (NASDAQ: OLMA) director receives grant of 29,500 stock options at $9.51 - Stock Titan
Olema Pharmaceuticals (OLMA) director awarded 29,500 stock options at $9.51 strike price - Stock Titan
Olema (OLMA) director Garland J. Scott awarded 29,500 stock options at $9.51 - Stock Titan
[Form 4] Olema Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Olema Pharmaceuticals (OLMA) director granted 29,500 stock options at $9.51 strike - Stock Titan
Olema (OLMA) director receives 29,500 options at $9.51 strike price - Stock Titan
Olema (OLMA) director granted 29,500 stock options at $9.51 exercise price - Stock Titan
Olema (NASDAQ: OLMA) director granted 29,500 stock options at $9.51 strike price - Stock Titan
Olema (OLMA) director Graham Walmsley awarded 29,500 stock options at $9.51 - Stock Titan
Olema Pharmaceuticals (NASDAQ: OLMA) investors approve board slate, pay plan and Ernst & Young - Stock Titan
What Prompted the Chief Legal Officer's Recent OLMA Share Sales - Kavout
Olema Pharmaceuticals | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plansmoomoo - Moomoo
Olema Pharmaceuticals Inc (OLMA) Institutional Confidence - TradingKey
Olema Pharmaceuticals Inc (OLMA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Olema Pharmaceuticals Inc (OLMA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Olema Pharmaceuticals Inc (OLMA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Olema Pharmaceuticals Inc (OLMA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Olema Pharmaceuticals Inc (OLMA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
How Olema Pharmaceuticals (OLMA) Is Adding Pipeline Depth Behind Its Palazestrant Breast Cancer Bet - Insider Monkey
10 Small Cap Stocks with Potential to Rise 1000 Percent - Insider Monkey
OLMA Stock Soars 47% in September So Far on Second PFE Deal - MSN
OLMA,GH Options - Finviz
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Olema Pharmaceuticals Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
J.P. Morgan Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating - Moomoo
Finanzdaten der Olema Pharmaceuticals Inc-Aktie (OLMA)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):